MedTrace Logo

Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML

NCT05305859 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-09-11

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of relapsed and/or refractory AML

Conditions

  • Leukemia, Myeloid, Acute
  • Relapsed Adult AML
  • Refractory Leukemia

Interventions

DRUG

venetoclax combining chidamide and azacitidine (VCA)

information already included in arm/group descriptions

Sponsors & Collaborators

  • Fujian Provincial Hospital

    collaborator OTHER

  • Fujian Cancer Hospital

    collaborator OTHER_GOV

  • Zhangzhou manicipal hospital of Fujian Province

    collaborator UNKNOWN

  • Jieyang People's Hospital

    collaborator OTHER

  • Dongguan People's Hospital

    collaborator OTHER_GOV

  • Huizhou Municipal Central Hospital

    collaborator OTHER

  • The First Affiliated Hospital of Xiamen University

    lead OTHER

Principal Investigators

  • Bing Xu · The First Affiliated Hospital of Xiamen University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-12
Primary Completion
2026-01-31
Completion
2027-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05305859 on ClinicalTrials.gov